Lv4
650 积分 2025-11-29 加入
中国脱髓鞘性视神经炎靶向生物制剂治疗专家共识（2026年）
2个月前
已完结
Evaluating inebilizumab in the treatment of generalized myasthenia gravis
4个月前
已完结
中国重症肌无力研究进展近十年回顾与展望
4个月前
已完结
Unexpected pregnancy in a patient with AQP4-IgG +NMOSD after treatment with inebilizumab: a case report
6个月前
已完结
中国腱鞘巨细胞瘤临床诊疗专家共识（2025年）
6个月前
已完结
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
7个月前
已完结
Neurological manifestations of immunoglobulin G4 related disease: a systematic review of 393 cases
7个月前
已完结
Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset
7个月前
已完结
Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis
8个月前
已完结
皖公网安备34019202002308
